Literature DB >> 25745185

Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib.

John C Byrd1, Peter Hillmen2, Danelle F James3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25745185     DOI： 10.1182/blood-2015-01-621466

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Authors:  Tracy E Wiczer; Lauren B Levine; Jessica Brumbaugh; Jessica Coggins; Qiuhong Zhao; Amy S Ruppert; Kerry Rogers; Anli McCoy; Luay Mousa; Avirup Guha; Nyla A Heerema; Kami Maddocks; Beth Christian; Leslie A Andritsos; Samantha Jaglowski; Steven Devine; Robert Baiocchi; Jennifer Woyach; Jeffrey Jones; Michael Grever; Kristie A Blum; John C Byrd; Farrukh T Awan
Journal:  Blood Adv       Date:  2017-09-08

Review 2.  Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.

Authors:  Esther S Kim; Sohita Dhillon
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

3.  Hypertension and incident cardiovascular events following ibrutinib initiation.

Authors:  Tyler Dickerson; Tracy Wiczer; Allyson Waller; Jennifer Philippon; Kyle Porter; Devin Haddad; Avirup Guha; Kerry A Rogers; Seema Bhat; John C Byrd; Jennifer A Woyach; Farrukh Awan; Daniel Addison
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

Review 4.  Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.

Authors:  Joanna Rhodes; Anthony Mato; Jeff P Sharman
Journal:  Curr Oncol Rep       Date:  2018-04-11       Impact factor: 5.075

Review 5.  Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.

Authors:  Maliha Khan; Jamie L Gibbons; Alessandra Ferrajoli
Journal:  Onco Targets Ther       Date:  2017-03-29       Impact factor: 4.147

6.  Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.

Authors:  Daniel Caldeira; Daniela Alves; João Costa; Joaquim J Ferreira; Fausto J Pinto
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

7.  Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.

Authors:  Yanhua Zhou; Hongtao Lu; Meifeng Yang; Chenhong Xu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 8.  BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia.

Authors:  Lorenzo Falchi; Jessica M Baron; Carrie Anne Orlikowski; Alessandra Ferrajoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-02-10       Impact factor: 2.576
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.